Europe Cervical Cancer Diagnostics Market & Forecast, By Test Type (Pap smear & HPV DNA) & Countries

Publisher Name :
Date: 13-Jun-2018
No. of pages: 163
Inquire Before Buying

Cervical cancer is one of the most serious public health issues in Europe. Despite introduction of vaccination in 21 European countries, still more than 23 Thousand women have died from cervical cancer across all over Europe. Cervical cancer incidence rate in Europe was 10.2 per 100,000 women population. Germany, France and United Kingdom are top three dominating countries in the Europe cervical cancer market in 2017. Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences.

Increasing cervical cancer incidence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing prevalence of HPV infections and increasing awareness about cervical cancer screening programs is also expected to drive the cervical cancer screening market in the near future.

Renub Research report titled “Europe Cervical Cancer Diagnostics Market & Forecast, By Test Type (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands)” provides a complete analysis of Europe Cervical Cancer Screening Market. The covers European Countries Cervical Cancer Test Market Screened Population & Mortality.

By Test Types – Pap smear Screening Tests is gaining popularity in Europe

The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests and HPV DNA Tests. Pap smear and HPV DNA tests are more popular with the developed countries such as Germany, United Kingdom and France.

By Country – Germany holds the largest share by population and market in Cervical Cancer Test

The report studies the market/screened population of Nine big European countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands) which provides a complete country-wise analysis of Europe Cervical Cancer Screening Market.

Cervical Cancer Diagnostics Market

•    Pap Smear Tests Market
•    HPV DNA Tests Market

Cervical Cancer Test Population

•    Pap Smear Test Population
•    HPV DNA Test Population

Cervical Cancer Mortality Population of All 9 Countries

All the 9 Countries Studied in the Report are as Follows

1.    United Kingdom
2.    France
3.    Germany
4.    Italy
5.    Spain
6.    Sweden
7.    Switzerland
8.    Norway
9.    Netherlands

Europe Cervical Cancer Diagnostics Market & Forecast, By Test Type (Pap smear & HPV DNA) & Countries

Table of Contents

1. Executive Summary

2. Europe Cervical Cancer Test (Screening) Analysis

2.1 Europe Cervical Cancer Test Population

2.1.1 Pap smear Test Population
2.1.2 HPV DNA Test Population

2.2 Europe Cervical Cancer Test (Screening) Market

2.2.1 Pap Smear Test Market
2.2.2 HPV DNA Test Market

3. Market & Population Share – By Countries

3.1 Europe Cervical Cancer Test Population

3.1.1 Pap smear Population
3.1.2 HPV DNA Population

3.2 Market Share – By Countries

3.2.1 Pap smear Market
3.2.2 HPV DNA Market

4. United Kingdom – Cervical Cancer Test Analysis

4.1 Population – Cervical Cancer Test (Screening)

4.1.1 Pap smear Test Population
4.1.2 HPV DNA Test Population

4.2 United Kingdom Cervical Cancer Deaths

4.3 Market – Cervical Cancer Test (Screening)

4.3.1 Pap smear Test Market
4.3.2 HPV DNA Test Market

5. France – Cervical Cancer Test Analysis (2011 – 2024)

5.1 Population – Cervical Cancer Test (Screening)

5.1.1 Pap smear Test Population
5.1.2 HPV DNA Test Population

5.2 France Cervical Cancer Mortality

5.3 Market – Cervical Cancer Test (Screening)

5.3.1 Pap Smear Test Market
5.3.2 HPV DNA Test Market

6. Germany – Cervical Cancer Test Analysis (2011 – 2024)

6.1 Population – Cervical Cancer Test (Screening)

6.1.1 Pap smear Test Population
6.1.2 HPV DNA Test Population

6.2 Germany Cervical Cancer Mortality

6.3 Market – Cervical Cancer Test (Screening)

6.3.1 Pap Smear Test Market
6.3.2 HPV DNA Test Market

7. Italy – Cervical Cancer Test Analysis (2011 – 2024)

7.1 Population – Cervical Cancer Test (Screening)

7.1.1 Pap smear Test Population
7.1.2 HPV DNA Test Population

7.2 Italy Cervical Cancer Mortality

7.3 Market – Cervical Cancer Test (Screening)

7.3.1 Pap Smear Test Market
7.3.2 HPV DNA Test Market

8. Spain – Cervical Cancer Test Analysis (2011 – 2024)

8.1 Population – Cervical Cancer Test (Screening)

8.1.1 Pap smear Test Population
8.1.2 HPV DNA Test Population

8.2 Spain Cervical Cancer Mortality

8.3 Market – Cervical Cancer Test (Screening)

8.3.1 Pap Smear Test Market
8.3.2 HPV DNA Test Market

9. Sweden – Cervical Cancer Test Analysis (2011 – 2024)

9.1 Population – Cervical Cancer Test (Screening)

9.1.1 Pap smear Test Population
9.1.2 HPV DNA Test Population

9.2 Sweden Cervical Cancer Mortality

9.3 Market – Cervical Cancer Test (Screening)

9.3.1 Pap Smear Test Market
9.3.2 HPV DNA Test Market

10. Switzerland – Cervical Cancer Test Analysis (2011 – 2024)

10.1 Population – Cervical Cancer Test (Screening)

10.1.1 Pap smear Test Population
10.1.2 HPV DNA Test Population

10.2 Switzerland Cervical Cancer Mortality

10.3 Market – Cervical Cancer Test (Screening)

10.3.1 Pap Smear Test Market
10.3.2 HPV DNA Test Market

11. Norway – Cervical Cancer Test Analysis (2011 – 2024)

11.1 Population – Cervical Cancer Test (Screening)

11.1.1 Pap smear Test Population
11.1.2 HPV DNA Test Population

11.2 Norway Cervical Cancer Mortality

11.3 Market – Cervical Cancer Test (Screening)

11.3.1 Pap Smear Test Market
11.3.2 HPV DNA Test Market

12. Netherlands – Cervical Cancer Test Analysis (2011 – 2024)

12.1 Population – Cervical Cancer Test (Screening)

12.1.1 Pap smear Test Population
12.1.2 HPV DNA Test Population

12.2 Netherlands Cervical Cancer Mortality

12.3 Market – Cervical Cancer Test (Screening)

12.3.1 Pap Smear Test Market
12.3.2 HPV DNA Test Market

13. Growth Drivers

13.1 Rising Incidence of Cervical Cancer in United Kingdom
13.2 Huge Prevalence of HPV Infected Patients in Europe

14. Challenges

14.1 Introduction of HPV Vaccination Programs Globally
14.2 Hard to Prevent Cervical Cancer in Eastern Europe and Central Asia


List of Figures:

Figure 2‑1: Europe – Cervical Cancer Test Population (Million), 2011 – 2017
Figure 2‑2: Europe – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024
Figure 2‑3: Europe – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017
Figure 2‑4: Europe – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024
Figure 2‑5: Europe – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017
Figure 2‑6: Europe – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024
Figure 2‑7: Europe – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 2‑8: Europe – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 2‑9: Europe – Cervical Cancer Pap smear Test Market (Million US$), 2011 – 2017
Figure 2‑10: Europe – Forecast for Cervical Cancer Pap smear Test Market (Million US$), 2018 – 2024
Figure 2‑11: Europe – Cervical Cancer HPV DNA Test Market (Million US$), 2011 – 2017
Figure 2‑12: Europe – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2018 – 2024

Figure 3‑1: Europe – Cervical Cancer Test Population Share (%), 2011 – 2017
Figure 3‑2: Europe – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024
Figure 3‑3: Europe – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017
Figure 3‑4: Europe – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024
Figure 3‑5: Europe – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017
Figure 3‑6: Europe – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024
Figure 3‑7: Europe – Cervical Cancer Test Market Share (%), 2011 – 2017
Figure 3‑8: Europe – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024
Figure 3‑9: Europe – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017
Figure 3‑10: Europe – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024
Figure 3‑11: Europe – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017
Figure 3‑12: Europe – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024

Figure 4‑1: United Kingdom – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 4‑2: United Kingdom – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 4‑3: United Kingdom – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 4‑4: United Kingdom – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 4‑5: United Kingdom – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 4‑6: United Kingdom – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 4‑7: United Kingdom – Cervical Cancer Deaths (Number), 2011 – 2017
Figure 4‑8: United Kingdom – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 4‑9: United Kingdom – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 4‑10: United Kingdom – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 4‑11: United Kingdom – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 4‑12: United Kingdom – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 4‑13: United Kingdom – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

Figure 5‑1: France – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 5‑2: France – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 5‑3: France – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 5‑4: France – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 5‑5: France – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 5‑6: France – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 5‑7: France – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 5‑8: France – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 5‑9: France – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 5‑10: France – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 5‑11: France – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 5‑12: France – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 5‑13: France – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

Figure 6‑1: Germany – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 6‑2: Germany – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 6‑3: Germany – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 6‑4: Germany – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 6‑5: Germany – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 6‑6: Germany – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 6‑7: Germany – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 6‑8: Germany – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 6‑9: Germany – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 6‑10: Germany – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 6‑11: Germany – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 6‑12: Germany – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 6‑13: Germany – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

Figure 7‑1: Italy – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 7‑2: Italy – Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 7‑3: Italy – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 7‑4: Italy – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 7‑5: Italy – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 7‑6: Italy – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 7‑7: Italy – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 7‑8: Italy – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 7‑9: Italy – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 7‑10: Italy – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 7‑11: Italy – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 7‑12: Italy – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 7‑13: Italy – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

Figure 8‑1: Spain – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 8‑2: Spain – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 8‑3: Spain – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 8‑4: Spain – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 8‑5: Spain – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 8‑6: Spain – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 –2024
Figure 8‑7: Spain – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 8‑8: Spain – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 8‑9: Spain – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 8‑10: Spain – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 8‑11: Spain – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 8‑12: Spain – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 8‑13: Spain – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

Figure 9‑1: Sweden – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 9‑2: Sweden – Forecast for Cervical Cancer Pap smear Test Population (Thousand), 2018 – 2024
Figure 9‑3: Sweden – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 9‑4: Sweden – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 9‑5: Sweden – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 9‑6: Sweden – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 9‑7: Sweden – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 9‑8: Sweden – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 9‑9: Sweden – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 9‑10: Sweden – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 9‑11: Sweden – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 9‑12: Sweden – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 9‑13: Sweden – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 10‑1: Switzerland – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 10‑2: Switzerland – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 10‑3: Switzerland – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 10‑4: Switzerland – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 10‑5: Switzerland – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 10‑6: Switzerland – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 10‑7: Switzerland – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 10‑8: Switzerland – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 10‑9: Switzerland – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 10‑10: Switzerland – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 10‑11: Switzerland – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 10‑12: Switzerland – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 10‑13: Switzerland – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 11‑1: Norway – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 11‑2: Norway – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 11‑3: Norway – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 11‑4: Norway – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 11‑5: Norway – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 11‑6: Norway – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 11‑7: Norway – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 11‑8: Norway – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 11‑9: Norway – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 11‑10: Norway – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 11‑11: Norway – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 11‑12: Norway – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 11‑13: Norway – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 12‑1: Netherlands – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 12‑2: Netherlands – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 12‑3: Netherlands – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 12‑4: Netherlands – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 12‑5: Netherlands – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 12‑6: Netherlands – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 12‑7: Netherlands – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 12‑8: Netherlands – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 12‑9: Netherlands – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 12‑10: Netherlands – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 12‑11: Netherlands – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 12‑12: Netherlands – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 12‑13: Netherlands – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

List of Tables:

Table 13-1: United Kingdom – Number of Incidence Observed and Projected and their respective Age Standardized Rate, 2010 - 2025
Table 13-2: Europe – Prevalence of HPV among women with normal cervical cytology in Europe by country and study, 2016

  • Global Prostate Cancer Diagnostics Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 19-Jan-2023        Price: US 3450 Onwards        Pages: 100
    The report focuses on the Prostate Cancer Diagnostics market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream marke......
  • Global Checkpoint Inhibitors for Treating Cancer Market Research Report 2023
    Published: 07-Jan-2023        Price: US 2900 Onwards        Pages: 65
    Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1......
  • Global PSA Test Market Research Report 2023
    Published: 07-Jan-2023        Price: US 2900 Onwards        Pages: 91
    Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are usually reported as nanograms of PSA per milliliter (ng/mL) of blood. Highlights The global PSA Test market was valued at US$ 511 million in 2022 and is anticipated to re......
  • Global Circulating Tumor Cells (Ctcs) Detector Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 05-Jan-2023        Price: US 3450 Onwards        Pages: 106
    The report focuses on the Circulating Tumor Cells (Ctcs) Detector market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the down......
  • Global Prostate Cancer Diagnostics Market Research Report 2023
    Published: 03-Jan-2023        Price: US 2900 Onwards        Pages: 88
    The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others t......
  • Global Prostate Cancer Diagnostics Sales Market Report 2023
    Published: 02-Jan-2023        Price: US 4000 Onwards        Pages: 116
    The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others t......
  • Global Checkpoint Inhibitors for Treating Cancer Market Analysis 2017-2022 and Forecast 2023-2028
    Published: 28-Dec-2022        Price: US 2980 Onwards        Pages: 83
    Snapshot Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1......
  • Global Oncology Molecular Diagnostics Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 13-Dec-2022        Price: US 3450 Onwards        Pages: 97
    The report focuses on the Oncology Molecular Diagnostics market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream ma......
  • Global Lung Cancer Liquid Biopsy Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 06-Dec-2022        Price: US 3450 Onwards        Pages: 105
    The report focuses on the Lung Cancer Liquid Biopsy market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs